Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity.

Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" - nimble and focused biopharmaceutical and health technology companies.
immunovant

Immunovant

Enabling normal lives for patients with autoimmune diseases

Dermavant

Dermavant

Leading innovation in medical dermatology

Genevant

Genevant

Delivering results through RNA therapeutics

Proteovant

Proteovant

Degrading errant proteins to elevate patient health

kinevant

Kinevant

Developing a new therapy for sarcoidosis

hemavant

Hemavant

Exploring novel solutions for blood disorders

lysovant

Lysovant

Developing a novel endolysin for bacterial infections

affivant

Affivant

Developing bispecific antibodies for solid tumors

aruvant

Aruvant

Developing gene therapies for rare diseases

lokavant

Lokavant

Shifting the paradigm in clinical trial intelligence

vantai

Vant.AI

Expanding the boundaries of in-silico drug design

datavant

Datavant

Organizing the world's healthcare data

cytovant

Cytovant

Developing novel and innovative cellular therapeutics in Asia

Roivant Health is our platform for founding and funding innovative digital health businesses.

As an integrated pharma-tech business, we hope to lead the transition to a more data-driven, patient-centric, and value-oriented health system. Companies we have built include Datavant, now the nation's largest health data ecosystem, and Lokavant, a leading clinical trial intelligence company creating operational transparency for sponsors and CROs.

Partners

gsk
affimed
eversana
gritstone
takeda
parexel
sarepta
sk
merck.jpg
michigan
biontech
cincinnati-childrens.jpg
astra-zeneca
duke
hanall
intron.jpg
dsp sumitomo
daiichi-sankyo.jpg
oxford-biomedica.jpg
medigene.jpg

We have a diverse pipeline of investigational drugs across our family of companies.

Roivant empowers a global team of innovators in the biopharmaceutical industry to expand the world of treatable conditions.

With offices in New York City, Boston, and Basel as well as remote working options, collaborating on a better future together has never been easier.
Grow With Roivant
Management Vant Leadership Board Members

Matt Gline

Chief Executive Officer

Eric Venker, MD

President & Chief Operating Officer

Mayukh Sukhatme

President & Chief Investment Officer

Frank Torti, MD

Vant Chair

Srini Ramanathan, PhD

Chief Development Officer

Richard Pulik

Chief Financial Officer

Rakhi Kumar

Chief Accounting Officer

Jo Chen

General Counsel

Woody Sherman, PhD

Chief Computational Scientist

Alex Gasner

EVP, Roivant Health

Matt Maisak

Chief Operating Officer, Roivant Platforms

Pete Salzmann, MD, MBA

CEO, Immunovant

Todd Zavodnick

CEO, Dermavant

Bill Gerhart

CEO, Kinevant

William Chou, MD

CEO, Aruvant

Pete Lutwyche

CEO, Genevant

Drew Fromkin

CEO, Proteovant

Lindsay Androski

CEO, Roivant Social Ventures

Benjamin Zimmer

CEO, Priovant

Rohit Nambisan

CEO, Lokavant

John Xu, MD

President, Cytovant

Bill Macias, MD, PhD

Chief Medical Officer, Immunovant

Chris Chapman

Chief Commercial Officer, Dermavant

Chris Van Tuyl

Chief Legal Officer, Dermavant

Christopher Winter, PhD

Head of Portfolio Strategy, Roivant Discovery

David Rubenstein, MD, PhD

Chief Scientific Officer, Dermavant

Huafeng Xu, PhD

CTO, Roivant Discovery

James Heyes, PhD

Chief Scientific Officer, Genevant

John Alfano

Chief Operating Officer, Lokavant

Julia G. Butchko

Chief Development & Technology Officer, Immunovant

Michael Swartzburg

Chief Financial Officer, Dermavant

Pamela Carroll, PhD

Chief Business Officer, Roivant Discovery

Paul Seaback

Chief Technical Officer, Dermavant

Pete Zorn

Chief Legal Officer, Genevant

Philip Brown, MD, JD

Chief Medical Officer, Dermavant

Matt Gline

Chief Executive Officer

Vivek Ramaswamy

Chairman

Andrew Lo

Director

Patrick Machado

Director

Ilan Oren

Director

Daniel Gold

Director

Masayo Tada

Director

James C. Momtazee

Director

Keith Manchester

Director

Roivant's drug discovery capabilities are driven by our industry-leading computational platform, which combines preeminent physics-based simulation tools with machine learning to generate unprecedented predictive power that can tackle previously intractable challenges.

The tight integration of our computational platform with our broad experimental capabilities and deep drug discovery experience enables the rapid design and optimization of new drugs to address a wide range of targets for diseases with high unmet need.
Learn More
NEW YORK

Roivant Sciences, Inc.

151 W 42nd Street

15th Floor

New York, NY 10036

United States

BOSTON

Roivant Sciences, Inc.

451 D Street

Boston, MA 02210

United States

BASEL

Roivant Sciences GmbH

Viaduktstrasse 8

4051 Basel

Switzerland